The 60-second version of Zenlabs Ethica Limited — what it does, how it earns, and who it competes with, before any of the numbers below.
No clear supporting case emerges from the available numbers.
| Metric | FY23 | FY24 | FY25 | FY26 | 3Y CAGR |
|---|---|---|---|---|---|
| Revenue | ₹67 Cr | ₹59 Cr | ₹51 Cr | ₹47 Cr | -11.1% |
| EBITDA | ₹3 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr | -12.1% |
| EBITDA Margin | 4.5% | 4.2% | 5.0% | 4.4% | — |
| PAT (Net Profit) | ₹0 Cr | ₹0 Cr | ₹0 Cr | -₹2 Cr | — |
| EPS | ₹0.75 | ₹0.65 | ₹0.41 | ₹-2.97 | — |
| ROE | 5.0% | 4.2% | 2.6% | -22.7% | — |
| ROCE | 8.6% | 10.4% | 10.7% | -10.1% | — |
| Total Debt | ₹6 Cr | ₹15 Cr | ₹13 Cr | ₹11 Cr | +23.4% |
| Free Cash Flow | -₹0 Cr | -₹9 Cr | ₹4 Cr | ₹4 Cr | — |
| Company | P/E | ROE |
|---|---|---|
| DR. REDDY S LABORATORIES | 31.0x | 8.8% |
| APOLLO HOSPITALS ENTER. L | 54.3x | 22.0% |
Poor scores on business quality without a price low enough to compensate. There is no obvious argument for owning this over a stronger company at a similar valuation. 4 high-severity red flags sit above this conclusion and should be read first.